GeoVax Accelerates GEO-MVA Vaccine Development Amid Global Mpox Crisis
GeoVax Labs, Inc. is expediting the development of its GEO-MVA Mpox vaccine in response to a global surge in cases and the WHO's reaffirmation of Mpox as a public health emergency, highlighting the urgent need for scalable and equitable vaccine solutions.
GeoVax Labs, Inc. has announced an accelerated development strategy for its GEO-MVA Mpox vaccine candidate, responding to the World Health Organization's (WHO) reaffirmation of Mpox as a Public Health Emergency of International Concern (PHEIC) and a significant surge in cases, particularly in Africa. The situation is exacerbated by the emergence of more virulent Mpox strains, Clade I and Clade 1a, and critical shortages in vaccine supply, with only 700,000 doses administered across 11 countries.
The European Medicines Agency (EMA) has provided favorable scientific advice, supporting a streamlined regulatory pathway for GEO-MVA, which could lead to expedited development and conditional approval in the EU. This development is crucial as global cases exceed 21,000 in 2025, with Africa's healthcare systems under severe strain due to aid reductions and the complexity of armed conflicts and infrastructure collapse.
GeoVax's response includes accelerating clinical development, advancing manufacturing capabilities for large-scale production, and engaging in international collaboration to ensure equitable access to the vaccine. The company's efforts are aimed at addressing the urgent global need for diversified and scalable vaccine platforms to combat the Mpox crisis effectively.